Literature DB >> 886843

A graded organ culture assay for the detection of Mullerian inhibiting substance.

P K Donahoe, Y Ito, W H Hendren.   

Abstract

Mesh：

Substances：

Year:  1977        PMID： 886843     DOI： 10.1016/0022-4804(77)90202-5

Source DB:  PubMed          Journal:  J Surg Res        ISSN： 0022-4804            Impact factor:   2.192


× No keyword cloud information.
  17 in total

1.  Tissue-engineered cells producing complex recombinant proteins inhibit ovarian cancer in vivo.

Authors:  A E Stephen; P T Masiakos; D L Segev; J P Vacanti; P K Donahoe; D T MacLaughlin
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-27       Impact factor: 11.205

2.  Müllerian Inhibiting Substance lowers testosterone in luteinizing hormone-stimulated rodents.

Authors:  A M Trbovich; P M Sluss; V M Laurich; F H O'Neill; D T MacLaughlin; P K Donahoe; J Teixeira
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-06       Impact factor: 11.205

3.  Mullerian inhibiting substance inhibits invasion and migration of epithelial cancer cell lines.

Authors:  Henry L Chang; Rafael Pieretti-Vanmarcke; Fotini Nicolaou; Xianlin Li; Xiaolong Wei; David T MacLaughlin; Patricia K Donahoe
Journal:  Gynecol Oncol       Date:  2010-11-06       Impact factor: 5.482

4.  Molecular differentiation of the mouse genital tract: serum-free organ culture system for morphological and biochemical correlations.

Authors:  R R Newbold; D B Carter; S E Harris; J A McLachlan
Journal:  In Vitro       Date:  1981-01

5.  Dissociation between testicular organogenesis and endocrine cytodifferentiation of Sertoli cells.

Authors:  S Magre; A Jost
Journal:  Proc Natl Acad Sci U S A       Date:  1984-12       Impact factor: 11.205

6.  Development of an efficiently cleaved, bioactive, highly pure FLAG-tagged recombinant human Mullerian Inhibiting Substance.

Authors:  Thanos D Papakostas; Rafael Pieretti-Vanmarcke; Fotini Nicolaou; Aristomenis Thanos; George Trichonas; Xanthi Koufomichali; Kosisochukwu Anago; Patricia K Donahoe; Jose Teixeira; David T MacLaughlin; Demetrios Vavvas
Journal:  Protein Expr Purif       Date:  2009-09-13       Impact factor: 1.650

7.  An albumin leader sequence coupled with a cleavage site modification enhances the yield of recombinant C-terminal Mullerian Inhibiting Substance.

Authors:  D Pépin; M Hoang; F Nicolaou; K Hendren; L A Benedict; A Al-Moujahed; A Sosulski; A Marmalidou; D Vavvas; P K Donahoe
Journal:  Technology       Date:  2013-09

8.  c-Jun N-terminal kinase inhibitor II (SP600125) activates Mullerian inhibiting substance type II receptor-mediated signal transduction.

Authors:  Nina Renlund; Rafael Pieretti-Vanmarcke; Francis H O'Neill; LiHua Zhang; Patricia K Donahoe; Jose Teixeira
Journal:  Endocrinology       Date:  2007-10-18       Impact factor: 4.736

9.  AAV9 delivering a modified human Mullerian inhibiting substance as a gene therapy in patient-derived xenografts of ovarian cancer.

Authors:  David Pépin; Amanda Sosulski; Lihua Zhang; Dan Wang; Vinod Vathipadiekal; Katherine Hendren; Caroline M Coletti; Aaron Yu; Cesar M Castro; Michael J Birrer; Guangping Gao; Patricia K Donahoe
Journal:  Proc Natl Acad Sci U S A       Date:  2015-07-27       Impact factor: 11.205

10.  Cell migration and activated PI3K/AKT-directed elongation in the developing rat Müllerian duct.

Authors:  Akihiro Fujino; Nelson A Arango; Yong Zhan; Thomas F Manganaro; Xianlin Li; David T MacLaughlin; Patricia K Donahoe
Journal:  Dev Biol       Date:  2008-11-05       Impact factor: 3.582
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.